CONTEXT AND OBJECTIVE: The term mastocytosis covers a group of rare disorders characterized by neoplastic proliferation and accumulation of clonal mast cells in one or more organs. The aim of this study was to assess the principal elements for diagnosing and treating these disorders. DESIGN AND SETTING: Narrative review of the literature conducted at Grupo Fleury, São Paulo, Brazil. METHODS: This study reviewed the scientific papers published in the PubMed, Embase (Excerpta Medica Database), Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde) and Cochrane Library databases that were identified using the search term "mastocytosis. " RESULTS: The clinical presentation of mastocytosis is remarkably heterogeneous and ranges from skin lesions that may regress spontaneously to aggressive forms associated with organ failure and short survival. Currently, seven subtypes of mastocytosis are recognized through the World Health Organization classification system for hematopoietic tumors. These disorders are diagnosed based on clinical manifestations and on identification of neoplastic mast cells using morphological, immunophenotypic, genetic and molecular methods. Abnormal mast cells display atypical and frequently spindle-shaped morphology, and aberrant expression of the CD25 and CD2 antigens. Elevation of serum tryptase is a common finding in some subtypes, and more than 90% of the patients present the D816V KIT mutation in mast cells. CONCLUSION: Here, we described the most common signs and symptoms among patients with mastocytosis and suggested a practical approach for the diagnosis, classification and initial clinical treatment of mastocytosis.
INTRODUCTION
Mastocytosis is currently defined as a heterogeneous group of disorders characterized by clonal expansion and accumulation of mast cells in one or more tissues, such as skin, bone marrow, liver, spleen, gastrointestinal tract and lymph nodes, among others. 1 Clonal mast cells are detected in most cases and in all subtypes of the disease. These clonal mast cells are most often characterized by the presence of the D816V-activating KIT mutation; however, other classes of KIT mutations have been detected. 2 Mastocytosis is considered to be one of the eight subcategories of myeloproliferative neoplasms, according to the 2008 World Health Organization classification system. 3 There are two ages of peak onset for this disease: in the first decade of life and between the fourth and fifth decades of life. 4, 5 The skin is the organ most affected in this class of disorders; in fact, the skin is infiltrated in virtually all children and around 85% of adults with mastocytosis. 4 The clinical presentation of mastocytosis is heterogeneous and ranges from disease limited to the skin (i.e. cutaneous mastocytosis) to cases with extracutaneous involvement (i.e. systemic mastocytosis). Cutaneous mastocytosis occurs mainly during infancy and childhood (i.e.
most cases appear within the first year of life) and is commonly associated with spontaneous regression of skin lesions, whereas systemic mastocytosis is usually diagnosed in adults and ranges from indolent to aggressive forms of mastocytosis. The latter is associated with multiorgan failure and decreased survival. 3 Mastocytosis is considered to be a rare disorder, but the true incidence and prevalence in the general population are unknown. In
Brazil, it can reasonably be assumed that the diagnosis of mastocytosis is greatly underestimated, given the low clinical awareness of the disease and the existence of very few specialized diagnostic centers.
OBJECTIVES
The aim of the present study was to review the main signs and symptoms of mastocytosis and suggest a practical approach for diagnosis, classification and initial management of patients with mast cell disorders.
METHODS
We conducted a narrative review by means of a systematic literature search using the PubMed, Embase (Excerpta Medica Database), Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde ) and Cochrane Library databases to identify published scientific papers relating to the search term "mastocytosis. " Moreover, the papers identified needed to focus on human subjects ( Table 1) .
RESULTS

Clinical manifestations
The clinical symptoms of mastocytosis are caused by acute and chronic release of intracytoplasmic mast cell mediators (i.e.
histamines, tryptase, prostaglandins and leukotrienes) and tissue infiltration by neoplastic mast cells. of children, and these extreme symptoms are more frequent in males. 4 In some cases, the allergic triggering factor is not identified, whereas in others, a history of medication use (e.g. aspirin,
nonsteroidal anti-inflammatory drugs and iodinated radiocontrast agents) or insect bites has been linked to the onset of symptoms. In mast cell leukemia, repeated severe episodes of massive release of mast cell mediators are typical, and these patients must be treated in intensive care units. In clinical subtypes other than mast cell leukemia, however, there may not be any direct relationship between mast cell mass, mast cell release and symptoms. 7 In many patients, the first sign of the disease is a characteristic maculopapular rash known as urticaria pigmentosa. The symptoms associated with these lesions are exacerbated with friction (Darier's sign). 7, 8 In aggressive forms, the massive tissue infiltration can lead to signs and symptoms secondary to the existence of hepatic or bone marrow infiltration. These additional signs and symptoms include abdominal pain, portal hypertension and ascites (i.e. relating to hepatic infiltration) and pancytopenia (i.e. relating to bone marrow infiltration).
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Diagnosis and classification of mastocytosis
The diagnosis of mastocytosis is based on identification of neoplastic mast cells by means of morphological, immunophenotypic and/or genetic methods. 10 The World Health Organization Diagnosing systemic mastocytosis requires identification of major and minor criteria in the patient's case history (Chart 1).
More specifically, the diagnosis of systemic mastocytosis is con- The percentage of mast cells in the bone marrow is decisive for the final diagnosis of systemic mastocytosis at advanced stages, and an increase in the number of mast cells to ≥ 5% suggests an unfavorable prognosis. In patients with mast cell leukemia, the number of mast cells in the bone marrow smear is ≥ 20%. The differential count should be performed in areas far from bone spicules, since mast cells tend to be present in higher numbers near the spicules. It should be noted that the limit of 20% applies only to bone marrow smears but not to histological sections. 22 In addition, a cytomorphological analysis contributes towards detection of eosinophilia, myelodysplasia and additional morphological features that might suggest coexistence with another hematological malignancy. A diff use pattern of infi ltration is the predominant pattern in aggressive systemic mastocytosis and mast cell leukemia. 23 In these patients, systemic mastocytosis can be diagnosed without additional tests, since the presence of one major criterion (i.e. aggregates of mast cells) and one minor criterion (i.e. 
Multiparameter flow cytometry
Immunophenotyping by means of flow cytometry provides relevant information for diagnosis, classification and monitoring of hematological malignancies. [27] [28] [29] [30] [31] Normal and reactive mast cells in the bone marrow present high forward and sideward light scatter characteristics and are promptly detected through strong expression of CD117. 32 The normal mast cell phenotype is characterized by expression of CD45, CD63, CD203c, FcRIe and cytoplasmic total tryptase (CyB12); and by absence of CD2, CD25, CD123 and CD34 antigens. 33, 34 HLA-DR is usually negative, but may also be partially expressed in a small fraction of normal individuals.
Mast cells in systemic mastocytosis patients frequently present aberrant antigenic expression, thereby allowing a means of clear differentiation from normal mast cells with diagnostic sensitivity higher than 98% and specificity of 100%. 32 Thus, multiparameter flow cytometry is highly informative in this setting and is currently considered to be the gold standard for identification of aberrant mast cells. 10 Neoplastic mast cells usually demonstrate aberrant expression of CD25, with or without CD2, and abnormal expression of these markers is considered to be a minor diagnostic criterion in the World Health Organization's classification system 10,32-37 (Chart 1, Figure 4 ). Other abnormal phenotypic profiles that have been described include aberrant expression of CD123; overexpression of CD203c, CD63, CD69 or CD45; and low expression of CyB12. 34, 38 It was recently shown that systemic mastocytosis is phenotypically heterogeneous and presents three different maturationassociated immunophenotypic profiles that correlate with molecular subtypes of the disease and have prognostic relevance. 33, 36 Patients with indolent systemic mastocytosis and clonal mast cell Expression of CD30 is also related to distinct subtypes of mastocytosis, i.e. it is strongly positive in cases of aggressive systemic mastocytosis and negative or dimly expressed in cases of indolent systemic mastocytosis.
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Serum tryptase
Serum tryptase levels are elevated in most patients with systemic mastocytosis, and detection of serum tryptase levels higher than 20 ng/ml is considered to be a minor diagnostic criterion in the World Health Organization's classification system. 1, 5, 40 Tryptase levels tend to be higher in patients with a high mast cell burden; patients with aggressive systemic mastocytosis generally present tryptase levels > 200 ng/ml, especially as the disease progresses. 41 However, tryptase levels are also elevated in a significant proportion of cases of acute myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndromes, and should not be considered to be a diagnostic criterion for patients with suspected myeloid neoplasms associated with mastocytosis. 3 Serum tryptase concentrations generally decrease after treatment of aggressive systemic mastocytosis and mast cell leukemia, thus making this a suitable marker for evaluating the response to cytoreductive drugs. 
c-KIT mutation and molecular studies
The KIT-D816V mutation is considered to be a minor diagnostic criterion according to the World Health Organization's classification system. Indeed, it is detected in more than 90% of cases of mastocytosis and, as the number of pathological cells in the sample increases, the likelihood of detecting the KIT mutation also increases. 2, 42 The sensitivity of KIT mutation detection can be increased by enriching the mast cells in the sample by fluorescence-activated cell sorting and use of highly sensitive polymerase chain reaction techniques. 1, 10 In suspected systemic mastocytosis cases, the analysis should be performed using bone marrow samples collected in ethylenediaminetetraacetic acid, and both non-fractionated and mononuclear bone marrow cells can be examined for the KIT mutation. Peripheral blood should not be used as an alternative to bone marrow, since the mutation is not found in the peripheral blood of most patients with indolent systemic mastocytosis. 1 Detection of the KIT mutation in the dermis is indicative of mastocytosis in the skin, but it is not diagnostically indicative of systemic involvement.
In rare cases of systemic mastocytosis, no KIT-D816V mutation is detected. In patients with small-sized mast cell infiltrates, a negative result must be interpreted with caution due to the small number of mast cells analyzed. Nevertheless, in aggressive systemic mastocytosis and suspected well differentiated systemic mastocytosis cases, demonstration of absence of D816V is clinically important since cases with wild type-KIT and certain types of KIT mutations other than D816V may respond to imatinib therapy. 19 If no mutation at codon 816 is detected, sequencing of KIT should be considered. 1 Moreover, in female patients without the KIT mutation, the pattern of chromosome X inactivation can be assessed by means of the human-androgen receptor-a gene (HUMARA) assay, in order to evaluate mast cell clonality. 25 In the presence of peripheral blood eosinophilia (> 1500 cells/ ml), investigation of the CHIC-2 deletion and FIP1L1-PDGFRA rearrangement by means of fluorescence in situ hybridization or the reverse transcriptase polymerase chain reaction is indicated. 1, 5, 40, 43 Moreover, detection of translocations in regions containing chromosome bands 5q31-5q33 via conventional cytogenetic analysis generally enables identification of cases associated with the PDGFRB rearrangement. 43, 44 Cases that have either a PDGFRA or PDGFRB mutation associated with mast cell hyperplasia should be properly classified as "myeloid neoplasms with PDGFRA or PDGFRB rearrangements, " according to the World Health Organization's classification system. . 59 However, clinical trials are required to confirm the clinical efficacy of these compounds. 
Chart 2. Triggering agents in mastocytosis
